A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging

A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging

Abstract Background Elacestrant is an oral selective estrogen receptor (ER) degrader. This phase 1b open-label, non-randomized study (RAD1901-106) was initiated to determine the effect of elacestrant on the availability of ER in lesions from postmenopausal women with ER+ advanced breast cancer (ABC)...

Full description

Bibliographic Details
Main Authors: Agnes Jager, Elisabeth G. E. de Vries, C. Willemien Menke-van der Houven van Oordt, Patrick Neven, Clasina M. Venema, Andor W. J. M. Glaudemans, Yamei Wang, Rebecca G. Bagley, Maureen G. Conlan, Philippe Aftimos
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Breast Cancer Research
Subjects:
Advanced breast cancer
Elacestrant
Endocrine therapy
Estrogen receptor
16α-18F-fluoro-17β-estradiol (FES)
Hormonal therapy
Online Access:http://link.springer.com/article/10.1186/s13058-020-01333-3

Internet

http://link.springer.com/article/10.1186/s13058-020-01333-3

Similar Items